Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that is marked by fasciculation, spasticity and progressive weakness of muscles, and results in difficulty speaking ...

Living near cyanobacterial blooms shortens survival in amyotrophic lateral sclerosis * Exposure to neurotoxic water sources ...

The Food and Drug Administration has granted Fast Track designation to AMX0114 for the treatment of amyotrophic lateral sclerosis (ALS).

CAMBRIDGE, Mass., June 03, 2025--Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis ...

Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study. Vandana Singh . Thu, Jun 5, 2025, 11:20 AM 3 min read. In This Article: ...

The experimental ALS treatment usnoflast exhibited promising signs of slowed functional decline and improved breathing in a ...

Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study. by Vandana Singh Benzinga Editor. Follow. Zinger Key Points.

Researchers have developed a gene therapy that significantly slowed motor function loss in preclinical models of amyotrophic ...

About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig’s disease or motor neuron disease, is a fatal degenerative neurologic disorder that affects more than 55,000 people in the ...

Living close to cyanobacterial harmful algal blooms—which are present nationwide but are more common in coastal and Great ...

Brainstorm Cell Therapeutics plans to launch a Phase 3b trial to test NurOwn against a placebo in about 200 people with mild ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering light by pointing to promising survival data.. The biopharma revealed in ...